Evidence map›Paper›PMID 40872300›Full record

ArticlePathogens (Basel, Switzerland)2025

Antiviral Activity of

Paula Peinsipp, Tanja Gerlza, Julia Kircher, Kurt Zatloukal, Corinna Jäger, Peter Pucher, Andreas J Kungl

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Paula PeinsippInstitute of Pharmaceutical Sciences, University of Graz, Schubertstraße 1, 8010 Graz, Austria.ORCID 0009-0000-4194-7119
Tanja GerlzaInstitute of Pharmaceutical Sciences, University of Graz, Schubertstraße 1, 8010 Graz, Austria.ORCID 0000-0003-4947-9721
Julia KircherInstitute of Pathology, Medical University of Graz, 8010 Graz, Austria.
Kurt ZatloukalInstitute of Pathology, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0001-5299-7218
Corinna JägerBDI-BioLife Science GmbH, Parkring 18, 8074 Raaba-Grambach, Austria.
Peter PucherBDI-BioLife Science GmbH, Parkring 18, 8074 Raaba-Grambach, Austria.
Andreas J KunglInstitute of Pharmaceutical Sciences, University of Graz, Schubertstraße 1, 8010 Graz, Austria.ORCID 0000-0003-3362-797X

Funding

BDI-BioLife Science GmbH BDI-2023-001
6 · The paper itself

Abstract

In this study, astaxanthin, which has previously been shown to have antiviral effects, was examined for its dose-dependent potency to inhibit cellular SARS-CoV-2 infections. Naturally occurring astaxanthin is obtained and orally administered as ASX-oleoresin, a composition of different astaxanthin fatty acid esters. We therefore hypothesized that the compound's beneficial effects are not only related to astaxanthin. Thus, a "green" algae extract (i.e., poor astaxanthin content < 0.2%; ASX

Indexed as

Antiviral AgentsChlorophyceaeChlorophytaCOVID-19 Drug TreatmentPlant ExtractsSARS-CoV-2AnimalsChlorocebus aethiopsCOVID-19HumansMicroalgaeXanthophyllsAntiviral AgentsastaxanthineoleoresinsPlant ExtractsXanthophyllsalgaeantiviral effectastaxanthinHaematococcus pluvialisSARS-CoV-2

Identifiers

PMID40872300
PMCPMC12389742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.